Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and earnings for the second quarter of 2023.
- Second-quarter revenue came in at $1.61 billion, which is up 1% year-over-year
- Earnings per share increased to $0.95 in the June quarter from $0.92 last year
- Adjusted earnings were $1.31 per share in Q2, compared to $1.25 per share in the second quarter of 2022
- The company reported second-quarter adjusted EBITDA of $530 million, which is up 4% annually
- The management expects full-year 2023 revenue to be in the range of $6.25 billion to $6.45 billion
- Adjusted EBITDA margin for 2023 is currently expected to be between 31.5% and 33.0%
Most Popular
NKE Earnings: Here’s everything you need to know about Nike’s Q1 report
Nike, Inc. (NYSE: NKE) on Thursday reported results for the first three months of fiscal 2024, reporting a modest rise in revenues. The sneaker giant reported net income of $1.45
Key takeaways from Accenture’s (ACN) Q4 2023 earnings report
Shares of Accenture plc (NYSE: ACN) were down 4% on Thursday after the company delivered mixed results for the fourth quarter of 2023 and provided full-year guidance that came below
CarMax (KMX) Q2 2024 Earnings: Key financials and quarterly highlights
CarMax, Inc. (NYSE: KMX) reported second quarter 2024 earnings results today. Net revenues were $7.1 billion, down 13.1% compared to the same period a year ago. Net earnings declined 5.8%
